Chronic Glucagon-Like Peptide-1 Infusion Sustains Left Ventricular Systolic Function and Prolongs Survival in the Spontaneously Hypertensive, Heart Failure–Prone Rat
- 1 September 2008
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Heart Failure
- Vol. 1 (3) , 153-160
- https://doi.org/10.1161/circheartfailure.108.766402
Abstract
Background— Glucagon-like peptide-1 (GLP-1) treatment leads to short-term improvements in myocardial function in ischemic and nonischemic cardiomyopathy. It is unknown whether GLP-1 improves survival when administered over a longer time period. Spontaneously hypertensive, heart failure–prone (SHHF) rats progress to advanced heart failure and death over a 15-month period. The authors sought to determine whether a continuous infusion of GLP-1 would reduce mortality in this model. Methods and Results— At 9 months of age, 50 SHHF rats were randomized to receive a 3-month, continuous infusion of either GLP-1 or saline. Metabolic parameters were measured and cardiac ultrasounds performed at study initiation and completion of treatment. Surviving rats were euthanized at 12 months. Hearts were perfused in an isolated, isovolumic heart preparation, and Tunel staining of myocardial samples was performed. Baseline metabolic and cardiac functional parameters were comparable. GLP-1–treated SHHF rats had greater surviv...Keywords
This publication has 42 references indexed in Scilit:
- Glucagon-Like Peptide-1 Infusion Improves Left Ventricular Ejection Fraction and Functional Status in Patients With Chronic Heart FailureJournal of Cardiac Failure, 2006
- Direct Effects of Glucagon-Like Peptide-1 on Myocardial Contractility and Glucose Uptake in Normal and Postischemic Isolated Rat HeartsThe Journal of Pharmacology and Experimental Therapeutics, 2006
- Low-intensity exercise training delays onset of decompensated heart failure in spontaneously hypertensive heart failure ratsAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Glucagon-like Peptide 1 Can Directly Protect the Heart Against Ischemia/Reperfusion InjuryDiabetes, 2005
- Glucagon-Like Peptide-1 Limits Myocardial Stunning following Brief Coronary Occlusion and Reperfusion in Conscious CaninesThe Journal of Pharmacology and Experimental Therapeutics, 2005
- Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated CardiomyopathyCirculation, 2004
- Effects of Glucagon-Like Peptide-1 in Patients With Acute Myocardial Infarction and Left Ventricular Dysfunction After Successful ReperfusionCirculation, 2004
- Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group studyThe Lancet, 2002
- Harnessing the Therapeutic Potential of Glucagon-Like Peptide-1Treatments in Endocrinology, 2002
- Glucagon‐like peptide‐1 (GLP‐1): a trial of treatment in non‐insulin‐dependent diabetes mellitusEuropean Journal of Clinical Investigation, 1997